Perpetual Ltd Sells 10,384 Shares of Humana Inc. $HUM

Key Points

• Perpetual Ltd reduced its Humana stake by 7.1%, selling 10,384 shares and retaining 136,402 shares valued at approximately $52.0 million. Institutional investors collectively own 92.38% of Humana.
• Analyst sentiment remains favorable, with 21 Buy, 10 Hold and one Sell rating; Humana has a “Moderate Buy” consensus and an average price target of $448.74.
• Humana exceeded quarterly expectations with $7.61 in EPS and $40.89 billion in revenue, while maintaining a quarterly dividend of $0.885 per share, or $3.54 annually.

Perpetual Ltd decreased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 7.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 136,402 shares of the insurance provider's stock after selling 10,384 shares during the quarter. Perpetual Ltd owned 0.11% of Humana worth $52,047,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in HUM. Wilkerson Advisory Group LLC grew its position in Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider's stock worth $66,000 after buying an additional 33 shares in the last quarter. Cidel Asset Management Inc. raised its holdings in Humana by 1.1% in the 2nd quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider's stock valued at $1,542,000 after acquiring an additional 41 shares in the last quarter. Bogart Wealth LLC raised its holdings in Humana by 192.0% in the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after acquiring an additional 48 shares in the last quarter. Fiduciary Alliance LLC raised its holdings in Humana by 0.9% in the 1st quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider's stock valued at $976,000 after acquiring an additional 49 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in shares of Humana by 20.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 324 shares of the insurance provider's stock worth $129,000 after acquiring an additional 54 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

HUM has been the topic of several recent research reports. Barclays lifted their price objective on Humana from $515.00 to $582.00 and gave the stock an "overweight" rating in a report on Friday. Zacks Research lowered Humana from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. upped their target price on Humana from $316.00 to $393.00 and gave the company a "neutral" rating in a research note on Monday, August 10th. Oppenheimer raised their target price on Humana from $475.00 to $525.00 and gave the stock an "outperform" rating in a research report on Monday. Finally, Robert W. Baird set a $596.00 price target on shares of Humana and gave the stock an "outperform" rating in a research note on Friday. Twenty-one investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $448.74.

Humana Price Performance

Shares of HUM stock opened at $432.24 on Tuesday. The stock's fifty day simple moving average is $389.75 and its 200 day simple moving average is $336.54. Humana Inc. has a one year low of $163.11 and a one year high of $456.50. The firm has a market cap of $51.90 billion, a price-to-earnings ratio of 40.89, a P/E/G ratio of 2.67 and a beta of 0.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analyst estimates of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%. The business's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company posted $6.27 earnings per share. On average, analysts expect that Humana Inc. will post 9.00 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 27th. Investors of record on Friday, October 30th will be given a dividend of $0.8850 per share. The ex-dividend date is Friday, October 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. Humana's dividend payout ratio (DPR) is 33.49%.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana reported that 95% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. The improvement could support higher quality-bonus payments in 2028, enhance benefits and improve the company’s competitive position. Humana Hits 95% Four-Star Coverage: What it Means for HUM
• Positive Sentiment: Raymond James upgraded HUM from “market perform” to “outperform” and set a $520 price target, implying roughly 20% upside from the referenced price. Robert W. Baird also upgraded the stock, adding to the bullish analyst momentum. Humana Raised to Outperform at Raymond James Financial
• Neutral Sentiment: Humana will release third-quarter 2026 results and 2026 guidance on November 6, followed by a management question-and-answer session. The report could provide confirmation—or challenge—to the recent rally and analysts’ earnings expectations. Humana to Release Third Quarter 2026 Results
• Neutral Sentiment: DataMeds AI’s Helomics ChemoFx cancer assay was added to Humana’s Medicaid coverage policy for certain gynecologic cancers. The move may expand access to testing and reimbursement, but the direct financial effect on Humana is likely limited. DataMeds AI Stock Rises After Humana Adds Medicaid Coverage
• Negative Sentiment: Analysts and market commentary have cautioned that Humana’s valuation may already reflect much of the star-rating recovery. With a referenced P/E ratio near 41, further gains may depend on earnings growth and successful execution. Humana’s Star Ratings Progress Doesn’t Erase Valuation Concerns

Humana Profile

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana's insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.